149 related articles for article (PubMed ID: 17223601)
1. Plasma levels of soluble vascular endothelial growth factor receptor-1 (sVEGFR-1) in familial Mediterranean fever.
Başar O; Oztürk MA; Köklü S; Ayaz S; Yüksel O; Kiraz S; Ertenli I; Calgüneri M
Joint Bone Spine; 2007 Jan; 74(1):52-5. PubMed ID: 17223601
[TBL] [Abstract][Full Text] [Related]
2. Interferon-gamma levels in familial Mediterranean fever.
Köklü S; Oztürk MA; Balci M; Yüksel O; Ertenli I; Kiraz S
Joint Bone Spine; 2005 Jan; 72(1):38-40. PubMed ID: 15681246
[TBL] [Abstract][Full Text] [Related]
3. Plasma and platelet serotonin levels in familial Mediterranean fever.
Onat AM; Ozçakar L; Oztürk MA; Uçar G; Ureten K; Dagli N; Kiraz S; Ertenli I; Calgüneri M
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S16-20. PubMed ID: 17949546
[TBL] [Abstract][Full Text] [Related]
4. Can the Thiol/Disulfide Imbalance Be a Predictor of Colchicine Resistance in Familial Mediterranean Fever?
Omma A; Sandikci SC; Kücüksahin O; Alisik M; Erel O
J Korean Med Sci; 2017 Oct; 32(10):1588-1594. PubMed ID: 28875601
[TBL] [Abstract][Full Text] [Related]
5. Is Familial Mediterranean Fever a thrombotic disease or not?
Demirel A; Celkan T; Kasapcopur O; Bilgen H; Ozkan A; Apak H; Arisoy N; Yildiz I
Eur J Pediatr; 2008 Mar; 167(3):279-85. PubMed ID: 17436016
[TBL] [Abstract][Full Text] [Related]
6. Colchicine modulates oxidative stress in serum and leucocytes from remission patients with Family Mediterranean Fever through regulation of Ca²+ release and the antioxidant system.
Sahin M; Uğuz AC; Demirkan H; Nazıroğlu M
J Membr Biol; 2011 Mar; 240(1):55-62. PubMed ID: 21249347
[TBL] [Abstract][Full Text] [Related]
7. Increased asymmetric dimethylarginine levels in young men with familial Mediterranean fever (FMF): is it early evidence of interaction between inflammation and endothelial dysfunction in FMF?
Terekeci HM; Oktenli C; Ozgurtas T; Nalbant S; Top C; Celik S; Tapan S; Kucukardali Y; Sanisoglu YS; Solmazgul E; Sahan B; Sayan O
J Rheumatol; 2008 Oct; 35(10):2024-9. PubMed ID: 18785307
[TBL] [Abstract][Full Text] [Related]
8. Effects of colchicine on inflammatory cytokines and selectins in familial Mediterranean fever.
Kiraz S; Ertenli I; Arici M; Calgüneri M; Haznedaroglu I; Celik I; Pay S; Kirazli S
Clin Exp Rheumatol; 1998; 16(6):721-4. PubMed ID: 9844766
[TBL] [Abstract][Full Text] [Related]
9. Plasma nitric oxide level in familial Mediterranean fever and its modulations by Immuno-Guard.
Panossian A; Hambartsumyan M; Panosyan L; Abrahamyan H; Mamikonyan G; Gabrielyan E; Amaryan G; Astvatsatryan V; Wikman G
Nitric Oxide; 2003 Sep; 9(2):103-10. PubMed ID: 14623176
[TBL] [Abstract][Full Text] [Related]
10. Chronic inflammation in FMF: markers, risk factors, outcomes and therapy.
Ben-Zvi I; Livneh A
Nat Rev Rheumatol; 2011 Feb; 7(2):105-12. PubMed ID: 21060333
[TBL] [Abstract][Full Text] [Related]
11. Association between colchicine resistance and vitamin D in familial Mediterranean fever.
Ozer I; Mete T; Turkeli Sezer O; Kolbasi Ozgen G; Kucuk GO; Kaya C; Kilic Kan E; Duman G; Ozturk Kurt HP
Ren Fail; 2015 Aug; 37(7):1122-5. PubMed ID: 26067744
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of hearing in pediatric familial Mediterranean fever patients during attack period and attack-free period.
Salimov A; Akyol U; Cildir B; Batu ED; Ozen S
Int J Pediatr Otorhinolaryngol; 2019 Apr; 119():185-192. PubMed ID: 30743166
[TBL] [Abstract][Full Text] [Related]
13. Do all colchicine preparations have the same effectiveness in patients with familial Mediterranean fever?
Baglan E; Ozdel S; Bulbul M
Mod Rheumatol; 2021 Mar; 31(2):481-484. PubMed ID: 32613873
[TBL] [Abstract][Full Text] [Related]
14. The significance of urinary beta-2 microglobulin level for differential diagnosis of familial Mediterranean fever and acute appendicitis.
Ugan Y; Korkmaz H; Dogru A; Koca YS; Balkarlı A; Aylak F; Tunc SE
Clin Rheumatol; 2016 Jul; 35(7):1669-72. PubMed ID: 26873102
[TBL] [Abstract][Full Text] [Related]
15. Serum interleukin 17 and interleukin 18 levels in familial Mediterranean fever.
Haznedaroglu S; Oztürk MA; Sancak B; Goker B; Onat AM; Bukan N; Ertenli I; Kiraz S; Calguneri M
Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S77-80. PubMed ID: 16273770
[TBL] [Abstract][Full Text] [Related]
16. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
Bilgen SA; Kilic L; Akdogan A; Kiraz S; Kalyoncu U; Karadag O; Ertenli I; Dogan I; Calguneri M
J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
[TBL] [Abstract][Full Text] [Related]
17. QT interval variability in familial Mediterranean fever: a study in colchicine-responsive and colchicine-resistant patients.
Nussinovitch U; Kaminer K; Nussinovitch M; Volovitz B; Lidar M; Nussinovitch N; Livneh A
Clin Rheumatol; 2012 May; 31(5):795-9. PubMed ID: 22271228
[TBL] [Abstract][Full Text] [Related]
18. Mean platelet volume in children with familial Mediterranean fever.
Makay B; Türkyilmaz Z; Unsal E
Clin Rheumatol; 2009 Aug; 28(8):975-8. PubMed ID: 19283330
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update.
Cerquaglia C; Diaco M; Nucera G; La Regina M; Montalto M; Manna R
Curr Drug Targets Inflamm Allergy; 2005 Feb; 4(1):117-24. PubMed ID: 15720245
[TBL] [Abstract][Full Text] [Related]
20. Colchicine therapy and the cognitive status of elderly patients with familial Mediterranean fever.
Leibovitz A; Lidar M; Baumoehl Y; Livneh A; Segal R
Isr Med Assoc J; 2006 Jul; 8(7):469-72. PubMed ID: 16889161
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
